公开(公告)号：US11230541B2

公开(公告)日：2022-01-25

申请号：US16634402

申请日：2018-07-26

申请人： Takeda Pharmaceutical Company Limited

发明人： Eiji Kimura ,  Masaki Ogino ,  Yasuhisa Kohara ,  Tomoko Ohashi ,  Tomohiro Kaku ,  Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito

IPC分类号： C07D409/12 ,  C07D401/12 ,  C07D249/18 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06

摘要： Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：USRE48334E1

公开(公告)日：2020-12-01

申请号：US15445251

申请日：2017-02-28

申请人： Takeda Pharmaceutical Company Limited

发明人： Junya Shirai ,  Hideyuki Sugiyama ,  Taku Kamei ,  Hironobu Maezaki

IPC分类号： C07D401/04 ,  C07D207/14 ,  C07D211/58 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08

摘要： The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle; ring B is an aromatic ring optionally having substituent(s); ring D is an aromatic ring optionally having substituent(s); L is a group represented by the formula R2, R3, R4a and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain; R1 is a hydrogen atom or a substituent; m and n are each independently an integer of 0 to 5; m+n is an integer of 2 to 5; and is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.

公开(公告)号：US20150141406A1

公开(公告)日：2015-05-21

申请号：US14404126

申请日：2013-05-31

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Hiroshi Nara ,  Masaki Daini ,  Akira Kaieda ,  Taku Kamei ,  Toshihiro Imaeda ,  Fumiaki Kikuchi

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

摘要翻译： 本发明提供具有优异的JAK抑制作用的化合物，其可用作预防或治疗自身免疫性疾病（类风湿性关节炎，牛皮癣，炎性肠病，干燥综合征，白塞病，多发性硬化，系统性红斑狼疮， 等），癌症（白血病，子宫平滑肌肉瘤，前列腺癌，多发性骨髓瘤，恶病质，骨髓纤维化等）等，或其盐。 本发明涉及由下式表示的化合物，其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US11952344B2

公开(公告)日：2024-04-09

申请号：US17754118

申请日：2020-09-25

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Yuya Oguro ,  Makoto Kamata ,  Shuhei Ikeda ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Shigemitsu Matsumoto ,  Hirotaka Kamitani ,  Takaharu Hirayama ,  Toshio Tanaka ,  Hiroshi Banno ,  Nobuyuki Takakura ,  Jinichi Yonemori ,  Takuya Fujimoto

IPC分类号： C07D213/61 ,  A61K31/444 ,  A61K31/495 ,  A61P25/00 ,  A61P29/00 ,  C07D211/04 ,  C07D213/65 ,  C07D213/68 ,  C07D221/04 ,  C07D237/08 ,  C07D239/26 ,  C07D239/34 ,  C07D333/38 ,  C07D401/12 ,  C07D405/02

CPC分类号： C07D211/04 ,  C07D237/08 ,  C07D239/26 ,  C07D405/02

摘要： Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

公开(公告)号：USRE49686E1

公开(公告)日：2023-10-10

申请号：US17076227

申请日：2020-10-21

申请人： Takeda Pharmaceutical Company Limited

发明人： Junya Shirai ,  Hideyuki Sugiyama ,  Taku Kamei ,  Hironobu Maezaki

IPC分类号： C07D401/04 ,  C07D207/14 ,  C07D211/58 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08

CPC分类号： C07D401/04 ,  C07D207/14 ,  C07D211/58 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08

摘要： The present invention relates to a compound represented by the formula




wherein ring A is a nitrogen-containing heterocycle;

ring B is an aromatic ring optionally having substituent(s);

ring D is an aromatic ring optionally having substituent(s);

L is a group represented by the formula





R2, R3, R4a ′ and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain;
R1 is a hydrogen atom or a substituent;
m and n are each independently an integer of 0 to 5;
m+n is an integer of 2 to 5; and
is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.

公开(公告)号：US20150094296A1

公开(公告)日：2015-04-02

申请号：US14388452

申请日：2013-03-27

申请人： Takeda Pharmaceutical Company Limited

发明人： Tetsuya Tsukamoto ,  Yusuke Ohba ,  Takafumi Yukawa ,  Hiroyuki Nagamiya ,  Taku Kamei ,  Norihito Tokunaga ,  Morihisa Saitoh ,  Atsutoshi Okabe

IPC分类号： C07D403/04 ,  C07D401/14 ,  C07D413/14 ,  C07D491/107 ,  C07D403/14 ,  C07D405/14

CPC分类号： C07D403/04 ,  A61K31/506 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D491/107

摘要： The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

摘要翻译： 本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣，类风湿性关节炎，炎性肠病，干燥综合征，白塞病，多发性硬化，系统性红斑狼疮等）等，其具有优异的Tyk2 抑制作用。 本发明涉及由下式表示的化合物，其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US11713311B2

公开(公告)日：2023-08-01

申请号：US17550173

申请日：2021-12-14

申请人： Takeda Pharmaceutical Company Limited

发明人： Eiji Kimura ,  Masaki Ogino ,  Yasuhisa Kohara ,  Tomoko Ohashi ,  Tomohiro Kaku ,  Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito

IPC分类号： C07D409/12 ,  C07D401/12 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18

CPC分类号： C07D409/12 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2095 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18 ,  C07D401/12

摘要： Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I):




wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US11702419B2

公开(公告)日：2023-07-18

申请号：US17201878

申请日：2021-03-15

申请人： Takeda Pharmaceutical Company Limited

发明人： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC分类号： C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

CPC分类号： C07D487/04 ,  A61K9/2095 ,  A61K9/4833 ,  A61P25/00 ,  C07D471/04

摘要： The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20160159773A1

公开(公告)日：2016-06-09

申请号：US14909427

申请日：2014-07-29

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Morihisa Saitoh ,  Takatoshi Yogo ,  Taku Kamei ,  Norihito Tokunaga ,  Yusuke Ohba ,  Takafumi Yukawa

IPC分类号： C07D401/14 ,  C07D413/14

CPC分类号： C07D401/14 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14

摘要： The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US10807987B2

公开(公告)日：2020-10-20

申请号：US16366710

申请日：2019-03-27

申请人： Takeda Pharmaceutical Company Limited

发明人： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC分类号： C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

摘要： The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.